Bolt Biotherapeutics, Inc. (BOLT) - 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Bolt Biotherapeutics, Inc. for the fiscal year ended December 31, 2025. Bolt is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer using its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform. The company is currently focused on the clinical development of BDC-4182 (targeting claudin 18.2) while other pipeline programs, including BDC-3042, are paused pending funding or partnerships. As of December 31, 2025, the company had 23 employees.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $7.7 million | $7.7 million |
| Net Loss | $(33.4) million | $(63.1) million |
| Research & Development Expenses | $28.5 million | $57.5 million |
| General & Administrative Expenses | $13.8 million | $18.5 million |
| Restructuring Charges | $1.5 million | $3.3 million |
| Cash, Cash Equivalents, and Marketable Securities | $31.8 million | $48.1 million |
| Accumulated Deficit | $(460.8) million | $(427.4) million |
| Net Cash Used in Operating Activities | $(39.9) million | $(61.3) million |
Note: The company has no debt obligations reported in the balance sheet. Liquidity is derived from cash, cash equivalents, and marketable securities.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $36.9 million (46%) year-over-year, driven by significant workforce reductions and the discontinuation of the trastuzumab imbotolimod program.
- Restructuring: The company executed two major restructuring plans in 2024 and 2025, reducing the workforce by approximately 50% in each instance to preserve cash. This resulted in $1.5 million in restructuring charges for 2025.
- Revenue Stability: Collaboration revenue remained flat at $7.7 million, derived from agreements with Toray, Genmab, and Innovent. The Innovent collaboration was restructured in 2024, resulting in a one-time payment recognized as other income in that year.
- Asset Impairment: Unlike 2024, which included a $1.5 million impairment charge on lease assets, no impairment charges were recorded in 2025.
Guidance, Outlook, and Risks
Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the filing date. Current cash and marketable securities of $31.8 million are projected to fund operations only into early 2027. The company will require substantial additional funding to advance clinical trials and operations.
Outlook: The company plans to raise capital through equity offerings, debt financings, or collaborations. It is prioritizing the Phase 1 dose escalation trial of BDC-4182. Other programs (CEA ISAC, PD-L1 ISAC, BDC-3042) are on hold.
Key Risks:
- Liquidity Risk: Inability to raise capital could force delays or termination of product development.
- Development Risk: The ISAC platform is unproven; clinical trials may fail to demonstrate safety or efficacy.
- Regulatory Risk: Dependence on FDA approval for commercialization; potential for clinical holds or rejection.
- Third-Party Dependence: Reliance on CDMOs for manufacturing and CROs for clinical trials.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any ongoing fundraising efforts or partnership negotiations.
- BDC-4182 Trial Status: Confirm the current enrollment numbers, safety data, and timeline for the Phase 1 dose escalation trial.
- Collaboration Terms: Review the remaining performance obligations and potential future revenue recognition from the Genmab and Toray agreements.
- Lease Obligations: Assess the impact of the Chesapeake Master Lease (expiring 2031) and the success of subleasing efforts to offset fixed costs.
- Stock-Based Compensation: Monitor the impact of the December 2025 stock option repricing on future expense recognition.